Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples

British Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2010, Pages 580-587

  Koechling, Wolfgang ^a   Hjortkjaer, Rolf ^a   Tankó, László B ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

Author keywords

abarelix; cetrorelix; degarelix; ganirelix; histamine; human skin

Indexed keywords

ABARELIX; CETRORELIX; COMPOUND 48-80; DEGARELIX; GANIRELIX; GONADORELIN ANTAGONIST; HISTAMINE;

ANAPHYLAXIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; HISTAMINE RELEASE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SKIN;

GONADOTROPIN-RELEASING HORMONE; HISTAMINE; HISTAMINE RELEASE; HUMANS; OLIGOPEPTIDES; SKIN;

EID: 77956605441     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03730.x     Document Type: Article

References (22)

1. Ring J, Brockow K, Behrendt H. History and classification of anaphylaxis. Novartis Found Symp 2004 257:6 16.
2. Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000 92:1074 1081.
3. Bagatell CJ, Conn PM, Bremner WJ. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men. Fertil Steril 1993 60:680 685.
4. Bagatell CJ, Rivier JE, Bremner WJ. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men. Fertil Steril 1995 64:139 145.
5. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004 115 (Suppl. 1 S44 S56.
6. FDA-Abarelix prescribing information 2005. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/021320s002lbl.pdf (Ref Type: Internet Communication).
7. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh A, Steger M, Schulz KD, Emons G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2003 90:552 559.
8. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001 44:453 467.
9. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008 180:1986 1992.
10. Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C. Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007 320:1113 1118.
11. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Olesen TK. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008 54:805 813.
12. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006 2:677 696.
13. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008 102:1531 1538.
14. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002 301:95 102.
15. Nilsson K, Bjermer L, Hellstrom S, Henriksson R, Hallgren R. A mast cell secretagogue, compound 48/80, prevents the accumulation of hyaluronan in lung tissue injured by ionizing irradiation. Am J Respir Cell Mol Biol 1990 2:199 205.
16. West GB. Histamine release from isolated and intact mast cells of two types of genetically different rat. Agents Actions 1982 12:98 100.
17. Pearce FL, Ali H, Barrett KE, Befus AD, Bienenstock J, Brostoff J, Ennis M, Flint KC, Hudspith B, Johnson NM. Functional characteristics of mucosal and connective tissue mast cells of man, the rat and other animals. Int Arch Allergy Appl Immunol 1985 77:274 276.
18. Ennis M, Lorenz W, Kapp B, Luben L, Schmal A. Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 1985 16:265 268.
19. Morgan JE, O'Neil CE, Coy DH, Hocart SJ, Nekola MV. Antagonistic analogs of luteinizing hormone-releasing hormone are mast cell secretagogues. Int Arch Allergy Appl Immunol 1986 80:70 5.
20. Hook WA, Karten M, Siraganian RP. Histamine release by structural analogs of LHRH. Fed Proc 1985 44:1323.
21. Schmidt F, Sundaram K, Thau RB, Bardin CW. Ac-D-NAL(2)1,4FD-Phe2,D-Trp3, D-Arg6-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 1984 29:283 289.
22. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab 2009 20:43 50.